Status:
COMPLETED
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
B-cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.
Eligibility Criteria
Inclusion
- Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).
- Stable disease or better for at least 3 months on most recent treatment
- Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study
- Adequate blood testing, liver, and kidney function as required by the study.
- Eligible subjects will allow tissue samples to be examined and stored.
Exclusion
- Patient has been treated with other investigational agents with a similar anti-tumor mechanism.
- Patient should not have failed more than 3 prior treatment regimens.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00097929
Start Date
May 1 2005
End Date
July 31 2006
Last Update
April 7 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.